Autologus peripheral stem cell transplantation in a patient with diffuse systemic sclerosis: Our experience;Trapianto autologo di cellule staminali periferiche in un paziente con sclerosi sistemica diffusa: Nostra esperienza

Reumatismo

Volumn 56, Issue 1, 2004, Pages 51-56

  Giorgetti, Francesco ^a,c   Minnucci, M L ^a   Santori, P ^a   Ercoli, L ^a   Rossi, M ^a   Del Papa, M ^a   Morico, G ^a   Squadroni, P ^a   Olivieri, A ^b   Centurioni, R ^a  

^a U O Med Int Sezione Camere   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Ospedale Civile   (Italy)

Author keywords

Autoimmune disease; Periferal blood stem cell transplantation; Systemic sclerosis

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FLUDARABINE; ILOPROST; LYMPHOCYTE ANTIBODY; PROTEIN ANTIBODY; PROTEIN ANTIBODY SCL70; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; UNCLASSIFIED DRUG; VALACICLOVIR;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIVIRAL ACTIVITY; AUTOTRANSPLANTATION; BONE MARROW CELL; CASE REPORT; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FIBROSIS; FOLLOW UP; GASTROINTESTINAL TRACT; HEART; HUMAN; LEUKAPHERESIS; LUNG; LUNG DISEASE; MALE; MORTALITY; PROGNOSIS; SKIN; SKIN DISEASE; STEM CELL TRANSPLANTATION; SYSTEMIC SCLEROSIS; VISCERA;

HUMANS; MALE; MIDDLE AGED; SCLERODERMA, DIFFUSE; STEM CELL TRANSPLANTATION;

EID: 11144355125     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Wigley FM. Systemic sclerosis - Clinical features. In: Klippel JH, Dieppe PA. Rheumatology, second edition. London: Mosby 1998.
2. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 299-305.
3. Denton CP, Black CM. Scleroderma and related disorders: therapeutic aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 17-35.
4. Furst DE, Clements PJ. D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol. 2001; 30: 189-91.
5. Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996; 35: 364-72.
6. Leighton C. Drug treatment of scleroderma. Drugs 2001; 61: 419-27.
7. Tyndall A, Black C, Finke J, Winkler J, Mertlesmann R, Peter HH, et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997; 349: 254.
8. Marmont AM. Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems. Haematologica 2001; 86: 337-45.
9. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, et al. Phase I/II trial of autologous transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-84.
10. Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M, Brooks P, et al. Autologus haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality. Bone Marrow Transplant 1999; 24: 729-34.
11. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 1997; 36: 390-2.
12. Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol Suppl. 1997; 48: 53-7.
13. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984; 27: 645-53.
14. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999; 42: 1168-78.
15. Marks RM, Czerniecki M, Andrews BS, Penny R. The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 1988; 31: 1524-34.
16. Maul GG, French BT, van Venrooij WJ, Jimenez SA. Topoisomerase I identified by scleroderma 70 antisera: enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci U S A 1986; 83: 5145-9.
17. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas-induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum 2001; 44: 1667-76.
18. Jelaska A, Kom JH. Role of apoptosis and transforming growth factor beta 1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000; 43: 2230-9.
19. Braun-Moscovici Y, Furste DE. Stem cell therapy in scleroderma. Curr Opin Rheumatol 2002; 14: 711-6.
20. Snowden JA, Patton WN, O'Donnell JL, Hannah EE, Hart DN. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997; 19: 1247-50.
21. Marmont AM. Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus? Lupus 1993; 2: 151-6.
22. Slavin S. Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rationale for ABMT. Bone Marrow Transplant 1993; 12: 85-8.
23. Burt RK, Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune disease by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002; 99: 768-84.
24. Marmont AM. New horizons in the treatment of autoimmune disease: immunoablation and stem cell transplantation. Ann Rev Med 2000; 51: 115-34.
25. Brodsky RA, Fuller AK, Ratner LE, Leffel MS, Jones RJ. Elimination of alloantibodies by immunoablative high-dose cyclophosphamide. Transplantation 2001; 71: 482-4.
26. Bingham SJ, Snowden J, Morgan G, Emery P. High dose immunosuppressive therapy and stem cell transplantation in autoimmune and inflammatory disease. Int Immunopharmacol 2002; 2: 399-414.
27. Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001; 60: 702-7.